NSI-189

NSI-189 is a new investigational antidepressant, which is purported to work differently from existing antidepressants. Researchers suggest this research chemical may potentially help those who do not respond to conventional medications. Research is also ongoing for its cognitive-enhancing effects.

According to the developer, NSI-189 is still currently in preclinical trials for a number of other conditions, including:

• Cognitive impairment and radiation-induced cognitive impairments
• Diabetic neuropathy, a form of nerve damage caused by diabetes
• Ischemic stroke
• Angelman Syndrome (a genetic disorder that causes developmental disabilities and nerve-related symptoms)

In the previously mentioned phase I trial of 24 people, those taking NSI-189 reported improvements in cognition according to self-reported questionnaires. Similarly, in the phase II trial of 220 people, the 40 mg dose was also associated with self-reported improvements in cognition, including improvements to memory, working memory, and executive function.

Click Here to view NeuroActive's Quality Assurance.